Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Income from Continuing Operations (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Income from Continuing Operations for 4 consecutive years, with 21143000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 71.62% to 21143000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 221057000.0, a 33.88% increase, with the full-year FY2025 number at 221057000.0, up 33.88% from a year prior.
  • Income from Continuing Operations was 21143000.0 for Q4 2025 at Phathom Pharmaceuticals, up from 29967000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 21143000.0 in Q4 2025 to a low of 94294000.0 in Q1 2025.
  • A 4-year average of 59649500.0 and a median of 53018500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 123.2% in 2024, then surged 71.62% in 2025.
  • Phathom Pharmaceuticals' Income from Continuing Operations stood at 54957000.0 in 2022, then plummeted by 44.76% to 79556000.0 in 2023, then increased by 6.36% to 74500000.0 in 2024, then soared by 71.62% to 21143000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Income from Continuing Operations are 21143000.0 (Q4 2025), 29967000.0 (Q3 2025), and 75653000.0 (Q2 2025).